Dr. Rubin on Advantages With Whole-Exome Sequencing

Mark A. Rubin, MD
Published: Thursday, Apr 28, 2016



Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

By using whole-exome sequencing, researchers are able to cover 20,000 genes and have the ability to detect neoantigens—two things that targeted sequencing does not offer, Rubin explains. Because tumors are sequenced in germline, researchers are also able to examine for risk factors in patients' germline DNA with whole-exome sequencing.

Targeted sequencing does still have a prominent role in early-stage cancer, Rubin adds. However, when patients have advanced disease and drug resistance, whole-exome sequencing provides a better platform to understand this resistance.


Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

By using whole-exome sequencing, researchers are able to cover 20,000 genes and have the ability to detect neoantigens—two things that targeted sequencing does not offer, Rubin explains. Because tumors are sequenced in germline, researchers are also able to examine for risk factors in patients' germline DNA with whole-exome sequencing.

Targeted sequencing does still have a prominent role in early-stage cancer, Rubin adds. However, when patients have advanced disease and drug resistance, whole-exome sequencing provides a better platform to understand this resistance.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x